Follow us on Twitter
twitter icon@FreshPatents


Steatohepatitis patents

      

This page is updated frequently with new Steatohepatitis-related patent applications.

Heterocyclic compounds useful in the treatment of disease
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (nash); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.. .

Aryl acylsulfonamides as blt1 antagonists
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene b4 receptor 1 (blt1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene b4 receptor 1 (blt1). The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer..

Ask1 inhibitor compounds and uses thereof
Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.. .

Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
The invention relates to double stranded ribonucleic acid (dsrnai) agents and compositions targeting the scap gene, as well as methods of inhibiting expression of a scap gene and methods of treating subjects having a scap-associated disorder, such as nonalcoholic fatty liver disease (nafld) or nonalcoholic steatohepatitis (nash), using such dsrnai agents and compositions.. .
Alnylam Pharmaceuticals, Inc.


Methods for diagnosing and evaluating non-alcoholic steatohepatitis
The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (nash), for determining the activity, the stage, or the severity of nash or for classifying a subject as a potential receiver or non receiver of a treatment of nash using circulating mirnas and other blood circulating markers of liver damage, e.g. Alpha 2 macroglobulin, hba1c, n-terminal pro-peptide of collagen type iii, mir-34 and mir-200.
Genfit


Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided.

Cb2 receptor internalization
Certain compounds and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor, including its internalization in a cell, are provided. Certain methods of identifying compounds that increase cb2 receptor internalization are also provided.
Arena Pharmaceuticals, Inc.


Gene signatures of inflammatory disorders that relate to the liver
This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (crohn's and ulcerative colitis).
Nstitut National De La Recherche Agronomique


Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an fgf21 (fibroblast growth factor 21) compound and a glp-1r (glucagon-like peptide-1 receptor) agonist with optimized glp-1r agonist/fgf21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (nash) and/or atherosclerosis..
Sanofi


Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
Disclosed herein are methods for use of r-chloroquine or clemizole or combinations of r-chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory′ conditions, treating liver cancer or reducing the risk of developing liver cancer in a subject.
Eiger Group International, Inc.


Temple University - Of The Commonwealth System Of Higher Education

. .

Systems, devices and methods for performing medical procedures in the intestine

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Fractyl Laboratories, Inc.

Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection..
The University Of British Columbia

Methods and compositions for treatment of non-alcoholic steatohepatitis

N is 1 or 2.. .

Fatty acid amides for the prevention and/or treatment of steatohepatitis

The invention relates to the use of fatty acid amides with phenylalkylamines and of a pharmaceutical composition comprising at least one of these compounds in the prevention and/or treatment of fatty liver or a pathological condition or disease caused by fatty liver, either alcoholic or non-alcoholic, and, in particular, for the prevention and/or treatment of the alcoholic steatohepatitis or non-alcoholic steatohepatitis (nash).. .
FundaciÓ Institut Mar D'investigacions MÈdiques

Novel composition for nonalcoholic fatty liver disease (nafld)

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited

Compositions and methods for the reduction or prevention of hepatic steatosis

Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof.
Nusirt Sciences, Inc.

Non-alcoholic fatty liver disease biomarkers

Methods, compositions, kits, and systems for characterizing the non-alcoholic fatty liver disease (nafld) state of a subject are provided. In some embodiments the methods, compositions, kits, and systems comprise at least one mirna selected from the differentially expressed mirnas listed in at least one of tables 1-4, 10-14, and 28-29.
The Regents Of The University Of California

Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Methods and compositions for use in treating, preventing or improving diseases related to the liver in an animal, including but not limited to nonalcoholic fatty liver disease (nafld), alcoholic liver disease (ald) or nonalcoholic steatohepatitis (nash), are described. The compounds of the present invention are gamma-ketoaldehyde scavengers..
Metabolic Technologies, Inc.

Method for screening pharmaceuticals for treatment of steatohepatitis using n-terminal dimerization of apoptosis signal-regulated kinase1

A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing n-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.. .
Wuhan University

Use of (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalene-2-yl) methanone in the prevention and/or treatment of non-alcoholic steatohepatitis

The present invention relates to (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalen-2-yl)methanone or one of the salts thereof, pharmaceutically acceptable for use in the prevention and/or treatment of hepatic steatosis, including non-alcoholic steatohepatitis or one of the complications of same.. .
Pierre Fabre Medicament

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Treatment for hepatic fibrosis

The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), employing the use of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid (aramchol) or a pharmaceutically acceptable salt thereof.
Galmed Research And Development Ltd.

Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer

This invention is directed to prostaglandin e2 receptor 4 (ep4) antagonists useful in the treatment of nonalcoholic steatohepatitis (nash)-associated liver cancer in a human or animal. The method comprises administering one or more of compound a, compound b or compound c, or pharmaceutically acceptable salts thereof, as the ep4 antagonist(s).
Askat Inc.

Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders

The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.. .
Deuterx, Llc

Methods of treating liver disease using indane acetic acid derivatives

This invention describes the use of indane acetic acid derivatives which are dual ppar delta/gamma agonists for the treatment of liver diseases including one or more of the following: nafld (non alcoholic fatty liver disease), nash (non alcoholic steatohepatitis), farber's disease, aclf (acute-on-chronic liver failure), clf (chronic liver failure), polt-hcv-svr (post-orthotopic liver transplant due to hepatitis c virus infection after sustained viral response following anti-hcv therapy), alagille syndrome, pfic (progressive familial intrahepatic cholestasis), pbc (primary biliary cirrhosis), primary sclerosing cholangitis, adpcld (autosomal dominant polycystic liver disease), treatment of liver transplant patients with reestablished fibrosis, cesd (cholesteryl ester storage disease), shtg (severe hypertriglyceridemia), hofh (homozygous familial hypercholesterolemia), he (hepatic encephalopathy), or alcoholic liver disease.. .
T3d Therapeutics, Inc.

Modulators of farnesoid x receptor and methods for the use thereof

Compounds, compositions and methods are provided for treating the fxr-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the fxr-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; inflammation, or cancer etc.. .
Xiamen University

Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of formula (ii): wherein r1, r2, r3, x and y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of formula (i): wherein r2, r3, and x, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
Pronova Biopharma Norge As

Method for discriminating symptom of hepatic disease

Provided is a noninvasive method for determining the presence of a symptom of a hepatic disease such as nonalcoholic fatty liver disease with a higher diagnostic accuracy. A method for discriminate between nonalcoholic fatty liver (nafl) and nonalcoholic steatohepatitis (nash), the method comprising: (1) a step of measuring the quantities of marker molecules contained in blood collected from a subject; (2) a step of determining an index value from a normalized score calculated based on the quantities of the marker molecules belonging to the same group; and (3) a step of determining that the subject is possibly affected with nash in the case that the index value is larger than a reference value..
Sumitomo Dainippon Pharma Co., Ltd.

Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others.
Volant Holdings Gmbh

Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies

The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (naflds) and/or nonalcoholic steatohepatitis (nash) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing nafld/nash using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor..
Remd Biotherapeutics, Inc.

Computerized optical analysis methods of mr (magnetic resonance) images for quantifying or determining liver lesions

A method computerized optically analyzes methods of conventional, preferably non-contrast-enhanced, mr (magnetic resonance) images of the liver. The method enables the detection of steatohepatitis by nash-mri and significant fibrosis by fibro-mri in patients suffering from nafld.
Centro De Investigacion Biomedica En Red (ciber)

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Methods and compositions for identifying non-alcoholic fatty liver disease

The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample..
The Regents Of The University Of California

Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (i), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same.
Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Heterocyclic compounds and methods of use

This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (nash); elevated cholesterol levels, and insulin resistance.. .
Medivation Technologies, Inc.

Pharmaceutical compositions for combination therapy

The present invention relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one lipid lowering agent (e.g., ppar-alpha agonist, ppar-delta agonist, ppar-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a fxr mediated disease or condition, such as primary biliary cirrhosis (pbc), primary sclerosing cholangitis (psc), portal hypertension, bile acid diarrhea, nafld (nonalcoholic fatty liver disease), nash (non-alcohol-induced steatohepatitis), and other chronic liver diseases.
Intercept Pharmaceuticals, Inc.

Treatment for non-alcoholic fatty liver diseases

The present invention relates to the use of mixtures of vitamin e and polyunsaturated fatty acids (pufas) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (nafld)—and/or non-alcoholic steatohepatitis (nash) in a subject in need thereof.
Dsm Ip Assets B.v.

Co-agonists of the glucagon and glp-1 receptors

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 receptor/gcg receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), and obesity. .
Merck Sharp & Dohme Corp.

Method of treating liver fibrosis

A method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms)..
Chemocentryx, Inc.

Methods of treating liver diseases

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2..
Zafgen, Inc.

Methods and compositions for the treatment of non-alcoholic steatohepatitis

The present disclosure relates to methods of preventing, treating, delaying the onset of, and delaying the progression of liver disease by administering topiramate in combination with phentermine to a patient in need thereof.. .
Vivus, Inc.

Use of nalmefene in non-alcoholic steatohepatitis

The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of nash, nafld, and/or ash.. .
Taiwanj Pharmaceuticals Co., Ltd.

Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)..
The Regents Of The University Of California

Methods of lowering serum cholesterol

Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an il-10 agent are also provided..

Adeno-associated viral vectors for the gene therapy of metabolic diseases

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors.
Universitat Autonoma De Barcelona

Cenicriviroc for the treatment of fibrosis

The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), or emerging cirrhosis..
Tobira Therapeutics ,inc.

Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)

Methods useful for sustaining a reduction of non-alcoholic steatohepatitis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof.
Nusirt Sciences, Inc.

Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss

The invention includes a method of preventing or treating a toxic liver disease or disorder, such as but not limited to non-alcoholic steatohepatitis (nash), liver injury associated with or caused by alcohol consumption in a mammal afflicted with nash, alcoholic hepatitis, drug induced liver injury, primary sclerosing cholangitis, viral hepatitis, liver fibrosis, liver cirrhosis, and other toxic liver conditions, in a subject, such as a mammal. The invention also includes a method of promoting weight loss in a subject, such as a mammal.
Yale University

Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided.
Somalogic, Inc.

Pharmaceutical compositions of berberine with epa and dha, and methods thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity.
Shenzhen Hightide Biopharmaceutical, Ltd.

Tiopronin prodrugs, pharmaceutical compositions thereof, and methods of use

Tiopronin prodrugs, pharmaceutical compositions comprising the tiopronin prodrugs, and methods of using tiopronin prodrugs and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, parkinson's disease, and huntington's disease.. .

Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 or a fragment thereof with a human antibody fc region. Also provided are health functional foods containing a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 (delta-like 1 homolog) or a fragment thereof with a human antibody fc region as an active ingredient..
Industry-academic Cooperation Foundation, Yonsei University

Heterocyclic modulators of lipid synthesis

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway.
3-v Biosciences, Inc.

Thyromimetics for the treatment of fatty liver diseases

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.. .
Metabasis Therapeutics, Inc.

Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine

Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.. .
Hadasit Medical Research Services And Development Ltd.

Daicel Corporation

. .

Uses of mito-ob transgenic mice

The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes.
University Of Manitoba

Novel composition for nonalcoholic fatty liver disease (nafld)

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited

Novel compounds as diacylglycerol acyltransferase inhibitors

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc

Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use

Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, n-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, n-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, parkinson's disease, and huntington's disease.. .

Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use

Cysteamine prodrugs, pharmaceutical compositions comprising the cysteamine prodrugs, and methods of using cysteamine prodrugs and pharmaceutical compositions thereof for treating eye, kidney, liver, metabolic, and neurological disorders such as cystinosis, cystinuria, non-alcoholic steatohepatitis, batten disease, leigh syndrome, and huntington's disease.. .

Pharmaceutical composition based on a hepatoprotector and prebiotic, and administrating

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.

International Nutrition Research Company

. .

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.
Shenzhen Hightide Biopharmaceutical, Ltd.

Compositions and methods for treating non-alcoholic steatohepatitis

Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatis (nash).. .
Mochida Pharmaceutical Co., Ltd.

Systems, devices and methods for performing medical procedures in the intestine

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Fractyl Laboratories, Inc.

Glucagon and glp-1 co-agonist compounds

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).. .
Eli Lilly And Company

Lysosomal acid lipase therapy for nafld and related diseases

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
Children's Hospital Medical Center

Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics

The invention provides a non-human animal model for non-alcoholic steatohepatitis (nash)-induced heptocellular carcinoma, methods of screening for agents for treating heptocellular carcinoma, methods of screening for targets useful in suppressing nash progression to heptocellular carcinoma, methods of treating heptocellular carcinoma, and compositions for treating the same.. .
The Regents Of The University Of California

Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelithiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.

Ketohexokinase (khk) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.. .
Alnylam Pharmaceuticals, Inc.

Differential diagnosis of liver disease

The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (nash) from nonalcoholic fatty liver (nafl) and non-nonalcoholic fatty liver disease (nafld), and normal controls.
The Regents Of The University Of California

International Nutrition Research Company

. .

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Treatment of hepatic fibrosis using an inhibitor of cbp/catenin

The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of hepatic fibrosis, including hepatic fibrosis associated with hepatitis, hepatic fibrosis associated with hepatitis b infection, and non-alcoholic steatohepatitis (nash), and pharmaceutical compositions comprising such alpha helix mimetic β-catenin inhibitors..

Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (nafld) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective pparγ agonist, int131 and optionally vitamin e or compositions thereof. Naflds that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (nash).
Intekrin Therapeutics, Inc.

International Nutrition Research Company

. .

Compositions and methods for prevention and treatment of metabolic steatosis and steatohepatitis

Choline.. .

Compositions and methods for treating non-alcoholic steatohepatitis

Compositions and methods for the treatment of non-alcoholic steatohepatitis and related disorders are provided herein, for example in women under 50 or pre-menopausal women.. .
Mochida Pharmaceutical Co., Ltd.

Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

Novel compounds as diacylglycerol acyltransferase inhibitors

This invention relates to novel compounds which are inhibitors of acyl coenzymea: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Intellectual Property (no.2) Limited

Novel 2,4-dinitrophenol formulations and methods using same

The present invention includes a low dose and sustained release formulation of 2,4-dinitrophenol (dnp). The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof..
Yale University

Biaryl derivatives as gpr120 agonists

The present invention relates to biaryl derivatives of formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of formula 1 according to the present invention promote glp-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation..
Lg Life Sciences Ltd.

A novel composition for nonalcoholic fatty liver disease (nafld)

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited

Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)..
The Regents Of The University Of California

Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis

Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (nash) measuring chi3l1 levels. In some embodiments, the methods described herein can distinguish nash from nonalcoholic fatty liver disease.
Yale University

Engineered polypeptides having enhanced duration of action

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Aegerion Pharmaceuticals, Inc.

Co-agonists of the glucagon and glp-1 receptors

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 receptor/gcg receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), and obesity.. .
Merck Sharp & Dohme Corp.

Highly soluble leptins

The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type i and type ii).
Aegerion Pharmaceuticals, Inc.

Gene signatures of inflammatory disorders that relate to the liver

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (crohn's and ulcerative colitis).
Institut National De La Recherche Agronomique

Novel compounds as diacylglycerol acyltransferase inhibitors

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc

Compositions and methods for the reduction or prevention of hepatic steatosis

Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof.
Nusirt Sciences, Inc.

New aryl-quinoline derivatives

Wherein r1, r2, r3, r4, r5, r6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (fabp) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases..

Methods of treating liver diseases

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2..
Zafgen, Inc.

Novel fatty acids and their use in conjugation to biomolecules

Wherein r1, r2, r3, r4, ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as gdf15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

Compositions and methods for treating non-alcoholic steatohepatitis

The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising epas.. .
Mochida Pharmaceutical Co., Ltd.